Mycobacterium tuberculosis carrying the rifampicin drug-resistance-conferring rpoB mutation H445Y is associated with suppressed immunity through type I interferons
mBio · 2023
DOI: 10.1128/mbio.00946-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2023. Verfasst von Suhas Bobba und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology, Washington University School of Medicine , St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Interferon Type I, Tuberculosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Tuberculosis (TB) is one of the leading causes of death due to an infectious disease. The rise of multi-drug resistance (MDR) in Mycobacterium tuberculosis ( Mtb ), the causative agent of TB, presents a significant obstacle to TB control. While human studies report dysregulated immune responses during MDR TB, a clear understanding of the host-pathogen interactions of MDR Mtb is lacking. Here, we studied the immune responses induced by Mtb strains carrying two of the most common rifampicin drug-resistance (RDR)-conferring single-nucleotide polymorphisms (SNPs) in the RNA polymerase gene of Mtb , which accounts for nearly 90% of drug-resistance mutations found clinically in Mtb . During Mtb infection of primary human macrophages, we found that pro-inflammatory cytokine production was reduced upon infection with Mtb carrying the H445Y SNP but not the S450L SNP. Using a mouse model, we also characterized the host immune response in vivo following infection. Despite similar establishment of Mtb infection in the lung and dissemination to the peripheral organs, we show that infection with the RDR Mtb rpoB -H445Y strain, but not with the rpoB -S450L strain, resulted in a suppressed lung myeloid and lymphoid immune responses through type I IFN-dependent pathways, relative to wt Mtb . This suppressed host immunity had functional consequences in limiting control of RDR Mtb strains harboring rpoB -H445Y and led to worse pathology during chronic TB disease. Collectively, our results suggest that disease pathogenesis may be associated with specific RDR mutations in Mtb , which may differentially regulate immune responses. IMPORTANCE This study highlights the impact of specific rifampicin-resistance-conferring mutations on the host immune response to Mycobacterium tuberculosis ( Mtb ), the causative agent of tuberculosis (TB). Clinical reports have previously suggested that multi-drug-resistant) TB patients exhibit altered peripheral immune responses as compared with their drug-sensitive TB counterparts. The murine model of infection with Mtb strains carrying drug-resistance-conferring mutations recapitulated these findings and allowed us to mechanistically interrogate the pathways responsible for driving the divergent immune responses. Our findings underscore the need for greater investigation into bacterial heterogeneity to better appreciate the diversity in host-pathogen interactions during TB disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Microbiology, Washington University School of Medicine , St. Louis, Missouri, USA.
- Department of Microbiology, University of Chicago , Chicago, Illinois, USA.
- Department of Epidemiology, Columbia University Mailman School of Public Health , New York, New York, USA.
- Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York, USA.
- Meakins-Christie Laboratories, Department of Medicine, McGill University , Montreal, Quebec, Canada.
- Department of Microbiology and Immunology, McGill International TB Centre , Montreal, Quebec, Canada.
ORCID-Profile: Shabaana A Khader
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- HHS | National Institutes of Health
- HHS | NIH | National Heart, Lung, and Blood Institute
Zitieren
APA
Bobba, S., Howard, N. C., Das, S., Ahmed, M., Tang, L., Thirunavukkarasu, S., Larsen, M. H., Mathema, B., Divangahi, M., & Khader, S. A. (2023). Mycobacterium tuberculosis carrying the rifampicin drug-resistance-conferring rpoB mutation H445Y is associated with suppressed immunity through type I interferons. mBio. https://doi.org/10.1128/mbio.00946-23
Vancouver
Bobba S, Howard NC, Das S, Ahmed M, Tang L, Thirunavukkarasu S, et al. Mycobacterium tuberculosis carrying the rifampicin drug-resistance-conferring rpoB mutation H445Y is associated with suppressed immunity through type I interferons. mBio. 2023. doi:10.1128/mbio.00946-23
BibTeX
@article{Bobba2023,
author = {Bobba, Suhas and Howard, Nicole C and Das, Shibali and Ahmed, Mushtaq and Tang, Linrui and Thirunavukkarasu, Shyamala and Larsen, Michelle H and Mathema, Barun and Divangahi, Maziar and Khader, Shabaana A},
title = {Mycobacterium tuberculosis carrying the rifampicin drug-resistance-conferring rpoB mutation H445Y is associated with suppressed immunity through type I interferons},
journal = {mBio},
year = {2023},
doi = {10.1128/mbio.00946-23}
}
EUVIMED